Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795022 | 1.00 | PTPN1 (0.46) | PTPN1CYP2C19MAPTCYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL2987835 | 0.99 | PTPN1 (0.45) | PTPN1CYP2C19MAPTCYP2C9CYP1A2 | |
| SCHEMBL7560152 | 0.82 | MAPT (0.47) | CYP2C19MAPTCYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL2983014 | 0.81 | PKM (0.57) | PTPN1CYP2C19MAPTPKMALDH1A1 | |
| SCHEMBL6259279 | 0.80 | TNIK (0.49) | CYP2C19MAPTCYP2C9CYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2990515 | 0.80 | PKM (0.55) | PTPN1CYP2C19MAPTPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL2990577 | 0.79 | TNIK (0.48) | CYP2C19MAPTCYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL30794377 | 0.78 | PTPN1 (0.48) | PTPN1CYP2C19MAPTCYP2C9CYP1A2 | |
| SCHEMBL6005423 | 0.78 | PTPN1 (0.48) | PTPN1CYP2C19MAPTCYP2C9CYP1A2 | |
| SCHEMBL1358811 | 0.77 | MAPT (0.63) | CYP2C19MAPTCYP2C9CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| CN-1759099-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2006-04-12 | — | — | CN | claimed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| CN-1759099-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2006-04-12 | — | — | CN | disclosed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1226107-B1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | CYP3A43, UGT2B7, CYP3A7 | PTPN1 2396/4885CYP2C19 11/4885MAPT 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.